Dmg Group, LLC Abb Vie Inc. Transaction History

Dmg Group, LLC

$121 Million
Q3 2024

A detailed history of Dmg Group, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Dmg Group, LLC holds 5,716 shares of ABBV stock, worth $943,082. This represents 0.93% of its overall portfolio holdings.

Number of Shares

5,716

Previous 5,752 0.63%

Holding current value

$943,082

Previous $986,000 14.4%

% of portfolio

0.93%

Previous 0.85%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	SELL	$163.84 - $199.33 $5,898 - $7,175	-36 Reduced 0.63%	5,716 $1.13 Million
Q2 2024 Jul 16, 2024	BUY	$154.79 - $180.76 $44,115 - $51,516	285 Added 5.21%	5,752 $986,000
Q1 2024 Apr 19, 2024	BUY	$159.82 - $182.1 $4,474 - $5,098	28 Added 0.51%	5,467 $995,000
Q4 2023 Jan 10, 2024	SELL	$137.6 - $154.97 $22,841 - $25,725	-166 Reduced 2.96%	5,439 $842,000
Q2 2023 Jul 13, 2023	SELL	$132.51 - $164.9 $4,770 - $5,936	-36 Reduced 0.64%	5,605 $755,000
Q1 2023 Apr 24, 2023	BUY	$144.61 - $166.54 $125,810 - $144,889	870 Added 18.24%	5,641 $905,000
Q4 2022 Feb 06, 2023	BUY	$138.31 - $165.87 $116,180 - $139,330	840 Added 21.37%	4,771 $775,000
Q3 2022 Oct 27, 2022	SELL	$134.21 - $153.93 $15,031 - $17,240	-112 Reduced 2.77%	3,931 $544,000
Q2 2022 Aug 09, 2022	BUY	$137.62 - $174.96 $3,165 - $4,024	23 Added 0.57%	4,043 $621,000
Q1 2022 Apr 25, 2022	BUY	$131.98 - $163.75 $23,360 - $28,983	177 Added 4.61%	4,020 $623,000
Q4 2021 Jan 31, 2022	BUY	$107.43 - $135.93 $412,853 - $522,378	3,843 New	3,843 $522,000

Others Institutions Holding ABBV

# of Institutions

3,841

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $292B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dmg Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dmg Group, LLC with notifications on news.

Account